Results 101 to 110 of about 157,671 (305)

Predictors of Relapse and Post‐Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome‐Negative B‐ALL

American Journal of Hematology, EarlyView.
Sankalp Arora, Hagop Kantarjian, Koji Sasaki, Nitin Jain, Zhouxuan Li, Wei Qiao, Sanam Loghavi, Guilin Tang, Caitlin Rausch, Farhad Ravandi, Fadi G. Haddad, Jayastu Senapati, Guillermo Montalban Bravo, Alexandre Bazinet, Rita Khouri, Rebecca Garris, Guillermo Garcia‐Manero, Nicholas J. Short, Elias Jabbour   +18 more
wiley   +1 more source

The evolution of the Pharma–CRO working relationship: AstraZeneca and Covance

, 2017
Christopher Bailey (AstraZeneca) and Lee Goodwin (Covance) speak to Sankeetha Nadarajah (Managing Commissioning Editor, Bioanalysis) about the evolution of the Pharma–CRO working relationship between AstraZeneca and Covance.

core   +1 more source

A retrospective observational analysis of post-pandemic influenza-related outcomes in the United Kingdom, 2010–2014

Human Vaccines & Immunotherapeutics, 2018
This study set out to evaluate influenza- and respiratory-related illnesses recorded during primary care physician consultations in England following the H1N1 pandemic in 2009 and to enable the development of a dynamic disease model.
Sankarasubramanian Rajaram, Witold Wiecek, Richard Lawson, Betina Blak, Yanli Zhao, Judith Hackett, Robert Brody, Tehseen Salimi, Billy Amzal, Vishal Patel   +9 more
doaj   +1 more source

Az AstraZeneca Kft. humán erőforrás fejlesztése

, 2010
Bevezetésképpen áttekinti az irodalmat, az emberi erőforrás fejlesztés jelentőségét és az ahhoz kapcsolódó kérdéseket. Ezután bemutatja a vizsgált szervezetet, az AstraZeneca vállalatot.
Kiss, Attila
core  

Represa de la vacunació amb Oxford/AstraZeneca: preguntes freqüents per a la ciutadania [fullet]

, 2021
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Vacunació; Oxford/AstraZeneca; Preguntes freqüentsCoronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Vaccination; Oxford/AstraZeneca; Frequently asked questionsCoronavirus SARS-CoV-2; COVID-19; 2,019-nCoV ...

core  

Geminale Difunktionalisierung von Ketonen durch C–S Bindungs‐insertion photogenerierter Donor–Donor Diazoverbindungen

Angewandte Chemie, EarlyView.
Die geminale Difunktionalisierung leicht verfügbarer Bausteine ermöglicht einen schnellen Zugang zu molekularer Komplexität. Diese Arbeit stellt eine Strategie vor, um zwei unterschiedliche funktionelle Gruppen an einem Carbonylkohlenstoff zu installieren, indem dieser in eine Donor–Donor‐Diazo‐Verbindung überführt wird. Die Methode ist sowohl im Batch‐
Vincent George, Aryaman Pattanaik, Daniel Maddox, Lukas M. Sigmund, Giovanna Mejia, Sara Pahlén, Simon O. Angerer, Maria Schmoll, Lisa Marie Schneider, Nidhal Selmi, Mikhail Kabeshov, Giulia Bergonzini, Julia Rehbein, Burkhard König   +13 more
wiley   +1 more source

Finanční analýza společnosti AstraZeneca

This bachelor's thesis focuses on the financial analysis of the AstraZeneca company. The thesis aims to assess the company's financial health and compare it to other companies within the same branch.
Maidaniuk, Varvara
core  

European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender

BJS (British Journal of Surgery), EarlyView., 2020
Recommendations for clinical and molecular identification of LS, surgical and endoscopic management of LS‐associated colorectal cancer and preventive measures for cancer were produced. The emphasis was on surgical and gastroenterological aspects of the cancer spectrum.
T. T. Seppälä, A. Latchford, I. Negoi, A. Sampaio Soares, R. Jimenez‐Rodriguez, L. Sánchez‐Guillén, D. G. Evans, N. Ryan, E. J. Crosbie, M. Dominguez‐Valentin, J. Burn, M. Kloor, M. von Knebel Doeberitz, F. J. B. van Duijnhoven, P. Quirke, J. R. Sampson, P. Møller, G. Möslein, on behalf of the European Hereditary Tumour Group (EHTG) and European Society of Coloproctology (ESCP)   +18 more
wiley   +1 more source

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment

Nature Communications
The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy.
Elizabeth L. Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa Carnevalli, Fernando J. Calero-Nieto, Gemma N. Jones, Andrew J. Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P. Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J. Carl Barrett, Arsene-Bienvenu Loembé, Serge Y. Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A. Nance, Carlos Alberto Gomez Roca, Elaine Cadogan, Susan E. Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I. Gabrilovich, Simon T. Barry   +55 more
doaj   +1 more source

Advancing isotope labeling technologies at AstraZeneca through academic-industrial collaboration [PDF]

Academic-Industrial collaborations have played an important role in developing new synthetic methodologies for the isotope chemistry team at AstraZeneca.
Artelsmair, Markus, Bragg, Ryan A., Kerr, William J., Bergare, Jonas, Elmore, Charles S., Skrydstrup, Troels   +5 more
core